Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy - Top-Institutions - MDSpire

Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy

  • By

  • Rinki Deo

  • Manish C Choudhary

  • Owen T Glover

  • Rachel Bender Ignacio

  • Julie Boucau

  • Kara W Chew

  • Carlee Moser

  • Judith S Currier

  • Joseph J Eron

  • Arzhang Cyrus Javan

  • Mark J Giganti

  • Evgenia Aga

  • Michael Gibbs

  • Taylor Cohen

  • Katie Streicher

  • Karina Soboleva

  • Courtney V Fletcher

  • Eric S Daar

  • Alexander L Greninger

  • Robert W Coombs

  • William Fischer

  • Michael D Hughes

  • Davey Smith

  • David Alain Wohl

  • Amy K Barczak

  • Jonathan Z Li

  • for the ACTIV-2/A5401 Study Team

  • September 8, 2025

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, MD

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • Clinical Trials

  • #2

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Infectious Diseases
    • Virology
    • Clinical Pharmacology

  • #3

    University of Washington School of Medicine
    University of Washington School of Medicine

    Seattle, WA

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • Clinical Trials

  • #4

    Massachusetts General Hospital (MGH)
    Massachusetts General Hospital (MGH)

    Boston, MA

    Key Differentiators

    • Infectious Diseases
    • Clinical Pharmacology
    • Virology

  • #5

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Infectious Diseases
    • Immunotherapy
    • Clinical Trials

Original Source(s)

Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy

  • by Rinki Deo, Manish C Choudhary, Owen T Glover, Rachel Bender Ignacio, Julie Boucau, Kara W Chew, Carlee Moser, Judith S Currier, Joseph J Eron, Arzhang Cyrus Javan, Mark J Giganti, Evgenia Aga, Michael Gibbs, Taylor Cohen, Katie Streicher, Karina Soboleva, Courtney V Fletcher, Eric S Daar, Alexander L Greninger, Robert W Coombs, William Fischer, Michael D Hughes, Davey Smith, David Alain Wohl, Amy K Barczak, Jonathan Z Li, for the ACTIV-2/A5401 Study Team

  • September 8, 2025

Related Content

Antibiotics May Not Help Mild COVID

A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.

Stewardship Cuts Steroid Prescribing

Behaviorally informed peer comparison feedback was associated with a gradual decline in glucocorticoid prescribing

Serum cytokine profiling reveals CXCL10 (IP-10) as a major predictor of severe COVID-19 outcomes in hospitalized patients during the first pandemic wave in Italy